Billiontoone, Inc. (NASDAQ:BLLN – Get Free Report) SVP Bosch John Roderick Ten sold 1,416 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $120.00, for a total value of $169,920.00. Following the completion of the sale, the senior vice president directly owned 33,552 shares in the company, valued at approximately $4,026,240. This represents a 4.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Bosch John Roderick Ten also recently made the following trade(s):
- On Monday, June 15th, Bosch John Roderick Ten sold 2,832 shares of Billiontoone stock. The stock was sold at an average price of $101.47, for a total transaction of $287,363.04.
Billiontoone Stock Up 2.0%
BLLN stock traded up $2.35 during trading on Wednesday, hitting $122.33. 687,667 shares of the stock traded hands, compared to its average volume of 479,467. Billiontoone, Inc. has a 1 year low of $61.96 and a 1 year high of $138.70. The firm’s 50 day moving average is $94.21 and its two-hundred day moving average is $87.39. The stock has a market cap of $5.63 billion and a price-to-earnings ratio of 222.42. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.58.
Analysts Set New Price Targets
A number of equities analysts recently weighed in on BLLN shares. Weiss Ratings upgraded shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. Wall Street Zen raised Billiontoone from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Guggenheim began coverage on Billiontoone in a report on Monday. They set a “buy” rating and a $125.00 price target on the stock. Wells Fargo & Company dropped their price objective on Billiontoone from $110.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 5th. Finally, JPMorgan Chase & Co. lifted their price objective on Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Billiontoone presently has an average rating of “Moderate Buy” and a consensus price target of $126.00.
View Our Latest Report on Billiontoone
Institutional Investors Weigh In On Billiontoone
Large investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC lifted its holdings in shares of Billiontoone by 26.1% during the 1st quarter. Perceptive Advisors LLC now owns 91,812 shares of the company’s stock valued at $7,248,000 after buying an additional 19,000 shares during the period. Bank of America Corp DE grew its holdings in shares of Billiontoone by 8,603.4% in the first quarter. Bank of America Corp DE now owns 12,707 shares of the company’s stock worth $1,003,000 after acquiring an additional 12,561 shares during the period. The Manufacturers Life Insurance Company increased its position in Billiontoone by 151.8% during the first quarter. The Manufacturers Life Insurance Company now owns 30,506 shares of the company’s stock valued at $2,408,000 after acquiring an additional 18,389 shares during the last quarter. Renaissance Technologies LLC bought a new position in Billiontoone in the first quarter valued at about $4,046,000. Finally, Public Employees Retirement System of Ohio purchased a new position in Billiontoone in the first quarter worth about $1,539,000.
About Billiontoone
BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.
BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.
Further Reading
- Five stocks we like better than Billiontoone
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Receive News & Ratings for Billiontoone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Billiontoone and related companies with MarketBeat.com's FREE daily email newsletter.
